Sequence information
Variant position: 182 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 285 The length of the canonical sequence.
Location on the sequence:
KDTFITHELAAEAAGNLVGP
R DFVSVRCAKRRGSTCVLAGM
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human KD-----------TFITHELAAEAAGNLVG---------------------------------PR DFVSVRCAKRRGSTCVLAGM
Mouse KD-----------TVITHELAAAAAGNLVG-----------
Rat KD-----------TVITHELAAAAAGNLVG-----------
Pig KD-----------TVITHELAAEAAGNLVG-----------
Bovine KD-----------TVITHELAAEVAGNLVG-----------
Sheep KD-----------TIITHELAAEAAGNLVG-----------
Horse KD-----------TVITHELAAESAGNLVG-----------
Chicken KD-----------TLITHETAAAPPGNIVG-----------
Xenopus laevis KD-----------TVITHEKAAETPGNIVG-----------
Zebrafish QE-----------TMITHEISAETPGNVVG-----------
Drosophila STFGSGNSSGSGADQLAHYVADLVGGKMNGAVIQSLSGPLA
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
Chain
64 – 285
Steroidogenic acute regulatory protein, mitochondrial
Domain
67 – 280
START
Modified residue
195 – 195
Phosphoserine; by PKA
Beta strand
182 – 192
Literature citations
The pathophysiology and genetics of congenital lipoid adrenal hyperplasia.
Bose H.S.; Sugawara T.; Strauss J.F. III; Miller W.L.;
N. Engl. J. Med. 335:1870-1878(1996)
Cited for: VARIANTS AH1 GLY-169; LYS-169; LEU-182; VAL-218; ARG-272 DEL AND PRO-275; CHARACTERIZATION OF VARIANTS AH1 GLY-169; LYS-169; LEU-182; VAL-218; ARG-272 DEL AND PRO-275; CATALYTIC ACTIVITY;
Disclaimer:
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.